Intellia Therapeutics Q2 EPS $(1.40) Misses $(1.32) Estimate, Sales $13.59M Miss $13.95M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intellia Therapeutics reported Q2 losses of $(1.40) per share, missing the analyst consensus estimate of $(1.32) by 6.06%. The company also reported quarterly sales of $13.59 million, missing the estimate of $13.95 million by 2.55%. This represents a decrease in both earnings and sales compared to the same period last year.
August 04, 2023 | 1:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Intellia Therapeutics' Q2 results missed estimates, with a higher loss per share and lower sales than expected. This could negatively impact the company's stock in the short term.
Intellia Therapeutics reported higher than expected losses and lower than expected sales for Q2. This underperformance compared to estimates and the same period last year could lead to a decrease in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100